Endocannabinoids are versatile molecules, regulating a variety of functions in the body. Daniele Piomelli explores how recent clinical trials testing rimonabant, an inhibitor of endocannabinoid signaling, for weight loss emerged from studies of individuals with schizophrenia; such trials have spurred basic research into how endocannabinoids affect both energy use and mood. Beat Lutz and Krisztina Monory examine how rimonabant might prove useful for preventing the development of adult epilepsy in response to fever-induced seizures in infants and young children.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dubé, C.M. et al. Trends Neurosci. 30, 490–496 (2007).
Chen, K. et al. J. Neurosci. 27, 46–58 (2007).
Marsicano, G. et al. Science 302, 84–88 (2003).
Chevaleyre, V. et al. Annu. Rev. Neurosci. 29, 37–76 (2006).
Monory, K. et al. Neuron 51, 455–466 (2006).
Ludányi, A. et al. J. Neurosci. 28, 2976–2990 (2008).
Chen, K. et al. Neuron 39, 599–611 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lutz, B., Monory, K. Soothing the seizures of children. Nat Med 14, 721–722 (2008). https://doi.org/10.1038/nm0708-721
Issue Date:
DOI: https://doi.org/10.1038/nm0708-721
